iCAD, Inc. (NASDAQ:ICAD – Get Rating) – Stock analysts at Oppenheimer raised their Q1 2023 earnings per share estimates for shares of iCAD in a research note issued to investors on Monday, April 3rd. Oppenheimer analyst F. Brisebois now forecasts that the technology company will post earnings of ($0.11) per share for the quarter, up from their prior forecast of ($0.13). Oppenheimer has a “Outperform” rating and a $4.00 price target on the stock. The consensus estimate for iCAD’s current full-year earnings is ($0.47) per share. Oppenheimer also issued estimates for iCAD’s Q2 2023 earnings at ($0.11) EPS, Q3 2023 earnings at ($0.08) EPS, Q4 2023 earnings at ($0.07) EPS and FY2023 earnings at ($0.37) EPS.
ICAD has been the topic of several other research reports. Lake Street Capital cut their price target on iCAD from $5.00 to $2.50 and set a “buy” rating on the stock in a research note on Wednesday, March 29th. StockNews.com began coverage on iCAD in a research report on Thursday, March 16th. They issued a “hold” rating on the stock. Finally, BTIG Research lowered their price target on iCAD from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Wednesday, March 29th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $4.50.
iCAD Stock Performance
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the business. Granahan Investment Management LLC lifted its stake in iCAD by 12.7% in the fourth quarter. Granahan Investment Management LLC now owns 2,849,124 shares of the technology company’s stock worth $5,214,000 after purchasing an additional 321,285 shares during the last quarter. Pura Vida Investments LLC grew its holdings in shares of iCAD by 25.9% during the fourth quarter. Pura Vida Investments LLC now owns 1,108,669 shares of the technology company’s stock valued at $2,029,000 after buying an additional 228,111 shares during the last quarter. Portolan Capital Management LLC acquired a new position in iCAD during the first quarter valued at $4,041,000. First Eagle Investment Management LLC raised its position in shares of iCAD by 32.7% in the fourth quarter. First Eagle Investment Management LLC now owns 728,484 shares of the technology company’s stock worth $1,333,000 after acquiring an additional 179,498 shares during the period. Finally, Essex Investment Management Co. LLC increased its stake in shares of iCAD by 44.8% during the third quarter. Essex Investment Management Co. LLC now owns 464,208 shares of the technology company’s stock worth $975,000 after purchasing an additional 143,658 shares in the last quarter. Institutional investors own 48.01% of the company’s stock.
Insiders Place Their Bets
In other news, insider Dana R. Brown acquired 40,000 shares of the business’s stock in a transaction dated Friday, March 31st. The stock was purchased at an average price of $1.30 per share, for a total transaction of $52,000.00. Following the completion of the transaction, the insider now directly owns 40,000 shares in the company, valued at approximately $52,000. The acquisition was disclosed in a filing with the SEC, which is available through this link. 12.50% of the stock is currently owned by company insiders.
iCAD Company Profile
iCAD, Inc is a medical technology company, which engages in the provision of cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments. The Cancer Detection segment includes image analysis and workflow products. The Cancer Therapy segment is composed of radiation therapy products.
Read More
- Get a free copy of the StockNews.com research report on iCAD (ICAD)
- Hypercharge Networks: Up Triple Digits, But What’s The Big Deal?
- 3 Reasons Why Apple’s 30% Rally Has Legs
- 3 Reasons to Pick First Citizens Instead of First Republic Bank
- 3 April Earnings Plays for Bullish Swing Traders
- Is Constellation Brands Star About To Rise?
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.
